natgillin/translations-raw huggingface dataset:
This includes the reports from Member States on their evaluation of Commission activities to support their actions on AMR. 
Te vključujejo poročila držav članic o njihovi oceni dejavnosti Komisije v podporo njihovim ukrepom v zvezi s protimikrobno odpornostjo.
It is clear from estimates made by ECDC that the health burden of AMR rose between 2007 and 2015. 
Iz ocen Evropskega centra za preprečevanje in obvladovanje bolezni (v nadaljnjem besedilu: ECDC) je jasno, da se je zdravstveno breme zaradi protimikrobne odpornosti med letoma 2007 in 2015 povečalo.
However, it is too early to tell if this trend has continued. 
Vendar je še prezgodaj za ugotovitve, ali se ta trend nadaljuje.
Updated estimates, based on data from 2016-2019 are expected to be available from ECDC in November 2020. 
Posodobljene ocene, ki temeljijo na podatkih iz obdobja 2016–2019, naj bi ECDC dal na voljo novembra 2020.
VI The Commission and ECDC provide support to the One Health approach to AMR since mid-2017 as soon as the action plan was adopted. 
Komisija in ECDC od sredine leta 2017, tj. takoj od sprejetja akcijskega načrta, podpirata pristop po načelu „enega zdravja“ k boju zoper protimikrobno odpornost.
The Commission and Member States regularly review AMR outcome indicators, published by ECDC, EFSA and EMA. 
Komisija in države članice redno pregledujejo kazalnike izidov v zvezi s protimikrobno odpornostjo, ki jih objavljajo ECDC, EFSA in EMA.
These include levels of resistant infection, AMR mortality and antibiotic consumption, reviewed in the EU Health Security Committee and the AMR One Health Network. 
Ti vključujejo ravni odpornih okužb, smrtnih primerov zaradi protimikrobne odpornosti in porabe protimikrobnih zdravil, ki sta jih pregledala Odbor EU za zdravstveno varnost in mreža „eno zdravje“ za boj zoper protimikrobno odpornost.
In the veterinary sector, sales of veterinary antimicrobial agents are used as an indicator under the European Surveillance of Veterinary Antimicrobial Consumption (ESVAC) project. 
V veterinarskem sektorju se prodaja veterinarskih protimikrobnih sredstev uporablja kot kazalnik v okviru projekta evropskega nadzora rabe protimikrobnih sredstev v veterini.
The new Regulation (EU) 2019/6 on veterinary medicinal products will strengthen this initiative, by providing for the legal obligation for Member States not only to collect data on sales, but also data on use per species of antimicrobials in animals. 
Nova uredba (EU) 2019/6 o zdravilih za uporabo v veterinarski medicini bo to pobudo še okrepila, saj bo zagotavljala, da bodo države članice pravno obvezane ne le zbirati podatke o prodaji, temveč tudi podatke o uporabi protimikrobnih zdravil pri živalih po posameznih vrstah.
This should allow the Member States and the Commission to further target their action against AMR. 
To bi moralo državam članicam in Komisiji omogočiti nadaljnje usmerjanje ukrepov zoper protimikrobno odpornost.
The AMR action plan fully recognizes the knowledge gap on the occurrence and spread of AMR in the environment and contains specific actions to close these gaps. 
Akcijski načrt zoper odpornost proti antimikrobikom v celoti priznava vrzel v znanju o pojavu in razširitvi protimikrobne odpornosti v okolju ter vsebuje posebne ukrepe za odpravo teh vrzeli.
Recently, the Commission adopted a communication on the EU strategic approach to pharmaceuticals in the environment which shows the Commission commitment in this area. 
Komisija je pred kratkim sprejela sporočilo o strateškem pristopu EU k farmacevtskim izdelkom v okolju, ki kaže zavezanost Komisije na tem področju.
VIII With regard to the antimicrobials market, there are many push incentives in place and the existing pharmaceutical legislation provides some pull incentives for innovative medicinal products. 
VIII. V zvezi s trgom antimikrobikov obstaja veliko pritegnitvenih spodbud, obstoječa farmacevtska zakonodaja pa zagotavlja nekatere pritegnitvene spodbude za inovativna zdravila.
The existing landscape has to be taken into account in the discussion about novel incentives or other mechanisms to address market failures with regard to the development and availability of antimicrobials. 
V razpravi o novih spodbudah ali drugih mehanizmih za odpravo nedelovanja trga v zvezi z razvojem in razpoložljivostjo antimikrobikov je treba upoštevati obstoječe razmere.
The new Regulation (EU) 2019/6 on veterinary medicinal products provides for a simplified assessment procedure and a data protection period, which may be extended up to 18 years under certain conditions. 
Nova uredba (EU) 2019/6 o zdravilih za uporabo v veterinarski medicini določa poenostavljen postopek ocene in obdobje varstva podatkov, ki se lahko pod določenimi pogoji podaljša do 18 let.
Such provisions intend notably to stimulate the development and enhance the availability of veterinary medicinal products, such as antimicrobial medicinal products. 
Namen takih določb je zlasti spodbuditi razvoj in povečati razpoložljivost zdravil za uporabo v veterinarski medicini, kot so protimikrobna zdravila.
The Commission has set out its overarching research strategy in its European One Health Action Plan against AMR, and it has funded the JPIAMR Strategic Research and Innovation Agenda. 
Komisija je svojo splošno raziskovalno strategijo določila v Evropskem akcijskem načrtu „eno zdravje“ zoper odpornost proti antimikrobikom ter vzpostavila strateški program za raziskave in inovacije, tj. skupno načrtovalno pobudo za zajezitev antimikrobične odpornosti.
INTRODUCTION 12 Member States hold the main responsibility for the organisation and delivery of healthcare. 
Države članice nosijo glavno odgovornost za organizacijo in izvajanje zdravstvenega varstva.
13 Decision (EU) 1082/2013 establishes the Early Warning and Response System (EWRS) and sets out specific criteria for alert notifications of serious cross-border health threats. 
1082/2013/EU vzpostavlja sistem zgodnjega obveščanja in odzivanja ter določa posebna merila za opozorila o resnih čezmejnih nevarnostih za zdravje.
National competent authorities must notify alerts only when a threat fulfils specific criteria. 
Pristojni nacionalni organi morajo opozorila objaviti samo, kadar nevarnost izpolnjuje posebna merila.
Thus, not all cases of AMR and healthcare associated infections that fall under epidemiological surveillance would be reported by the EWRS. 
To pomeni, da sistem zgodnjega obveščanja in odzivanja ne bi poročal o vseh primerih protimikrobne odpornosti in okužbah, povezanih z zdravstveno oskrbo, ki spadajo v epidemiološko spremljanje.
Box 1 - The role of EU agencies in AMR Additionally, EMA supports developers, in particular SMEs and academia and facilitates the development of antibiotics through dedicated schemes for innovative medicines such as the Innovative Task Force activities or the PRIME.1 OBSERVATIONS 36 The EU one Health action plan against AMR fully recognizes the knowledge gap on the occurrence and spread of AMR in the environment and contains specific actions to close these gaps. 
Okvir 1 – Vloga agencij EU na področju protimikrobne odpornosti Evropska agencija za zdravila (EMA) poleg tega podpira razvijalce, zlasti MSP in akademske institucije, ter spodbuja razvoj antibiotikov prek namenskih programov za inovativna zdravila, kot so dejavnosti projektne skupine za inovacije ali dejavnosti v okviru programa PRIME1. PRIPOMBE 36. Akcijski načrt EU zoper odpornost proti antimikrobikom „eno zdravje“ v celoti priznava vrzel v znanju o pojavu in razširitvi protimikrobne odpornosti v okolju ter vsebuje posebne ukrepe za odpravo teh vrzeli.
48 With regard to the antimicrobials market, there are many push incentives in place and the existing pharmaceutical legislation provides some pull incentives for innovative medicinal products. 
48. V zvezi s trgom antimikrobikov obstaja veliko pritegnitvenih spodbud, obstoječa farmacevtska zakonodaja pa zagotavlja nekatere pritegnitvene spodbude za inovativna zdravila.
The existing landscape has to be taken into account in the discussion about novel incentives or other mechanisms to address market failures with regard to the development and availability of antimicrobials. 
V razpravi o novih spodbudah ali drugih mehanizmih za odpravo nedelovanja trga v zvezi z razvojem in razpoložljivostjo antimikrobikov je treba upoštevati obstoječe razmere. 49.
49 The Commission has evaluated its financial investment in AMR research and innovation, through the mapping performed by JPIAMR (which was financed via an EU grant). 
Komisija je svoje finančne naložbe v raziskave in inovacije na področju protimikrobne odpornosti ocenila z evidentiranjem, izvedenim v okviru skupne načrtovalne pobude za zajezitev antimikrobične odpornosti (in financiranim z nepovratnimi sredstvi EU).
However, the full impact of this investment has not been comprehensively evaluated. 
Polni učinek te naložbe pa ni bil temeljito ocenjen.
55 The Commission has earmarked funding for the establishment of the new clinical trials network in 2021. 
55. Komisija je namenila sredstva za vzpostavitev novega omrežja kliničnih preskušanj v letu 2021.
57 The Commission has set out its overarching research strategy in its European One Health Action Plan against AMR, and it has funded the JPIAMR Strategic Research and Innovation Agenda. 
Komisija je svojo splošno raziskovalno strategijo določila v Evropskem akcijskem načrtu „eno zdravje“ zoper odpornost proti antimikrobikom ter vzpostavila strateški program za raziskave in inovacije, tj. skupno načrtovalno pobudo za zajezitev antimikrobične odpornosti.
However, the Commission acknowledges that some of the important challenges facing AMR research are not sufficiently addressed in the strategy. 
Vendar Komisija priznava, da v strategiji niso v zadostni meri obravnavani nekateri pomembni izzivi v okviru raziskav na področju protimikrobne odpornosti.
CONCLUSIONS AND RECOMMENDATIONS 66 The Commission and ECDC provide support to the One Health approach to AMR since mid-2017 when the action plan was adopted. 
ZAKLJUČKI IN PRIPOROČILA 66. Komisija in ECDC od sredine leta 2017, tj. od sprejetja akcijskega načrta, podpirata pristop po načelu „enega zdravja“ k boju zoper protimikrobno odpornost.
As statistics on outcomes generally take around two years to become available, it is too early to assess impacts or results in terms of reduction in health burden. 
Ker so statistični podatki o izidih običajno na voljo po dveh letih, je še prezgodaj za oceno učinkov ali rezultatov v smislu zmanjšanja zdravstvenega bremena.
68 The Commission and Member States regularly review the AMR outcome indicators which are published by the ECDC, EFSA and EMA. 
Komisija in države članice redno pregledujejo kazalnike izidov v zvezi s protimikrobno odpornostjo, ki jih objavljajo ECDC, EFSA in EMA.
These include levels of resistant infection, AMR mortality and antibiotic consumption which are reviewed in the EU Health Security Committee and in other forums Đ including the 2019 Romania Presidency Conference on AMR and the AMR One Health Network. 
Ti vključujejo ravni odpornih okužb, smrtnih primerov zaradi protimikrobne odpornosti in porabe protimikrobnih zdravil, ki se pregledujejo v okviru Odbora EU za zdravstveno varnost in drugih forumov – vključno s konferenco romunskega predsedstva o protimikrobni odpornosti leta 2019 in mrežo „eno zdravje“ za boj zoper protimikrobno odpornost.
The new Regulation (EU) 2019/6 on veterinary medicinal products will strengthen this initiative, by providing for the legal obligation for Member States not only to collect data on sales, but also data on use per species of antimicrobials in animals. 
SL SL 2
Reporting surveillance data on HAIs to the EU level is an obligation of Member States. 
Države članice so podatke o spremljanju okužb, povezanih z zdravstveno oskrbo, dolžne sporočati na ravni EU.
ECDC monitors and provides tools for improving such reporting by coordinating point prevalence surveys of HAIs and providing ÔlightŐ (minimum) surveillance protocols to encourage reporting by all Member States. 
ECDC spremlja in zagotavlja orodja za izboljšanje tega poročanja z usklajevanjem raziskav točkovne prevalence okužb, povezanih z zdravstveno oskrbo, in zagotavljanjem „lahkih“ (minimalnih) nadzornih protokolov za spodbujanje poročanja v vseh državah članicah.
The European One Health Action Plan against AMR fully recognizes the knowledge gap on the occurrence and spread of AMR in the environment and contains specific actions to close these gaps. 
Evropski akcijski načrt zoper odpornost proti antimikrobikom „eno zdravje“ v celoti priznava vrzel v znanju o pojavu in razširitvi protimikrobne odpornosti v okolju ter vsebuje posebne ukrepe za odpravo teh vrzeli.
Recently, the Commission adopted a communication on the EU strategic approach to pharmaceuticals in the environment2 which shows the Commission commitment in this area. 
Komisija je pred kratkim sprejela sporočilo o strateškem pristopu EU k farmacevtskim izdelkom v okolju2, ki kaže predanost Komisije na tem področju.
Recommendation 1 Đ Improving the EU response to AMR through better support to Member State national action plans The Commission accepts recommendation 1a The Commission accepts recommendation 1b. 
Priporočilo1 – Izboljšanje odziva EU na protimikrobno odpornost z boljšo podporo nacionalnim akcijskim načrtom držav članic Komisija sprejema priporočilo 1a. Komisija sprejema priporočilo 1b.
The Commission accepts recommendation 1c Recommendation 2 Đ Promoting better monitoring and the antimicrobials The Commission accepts recommendation 2. prudent use of veterinary 71 With regard to the antimicrobials market, there are many push incentives in place and the existing pharmaceutical legislation provides some pull incentives for innovative medicinal products. 
Priporočilo 2 – Spodbujanje preudarne uporabe antimikrobikov za uporabo v veterinarski medicini in boljšega nadzora nad protimikrobno odpornostjo Komisija sprejema priporočilo 2. 71. V zvezi s trgom antimikrobikov obstaja veliko pritegnitvenih spodbud, obstoječa farmacevtska zakonodaja pa zagotavlja nekatere pritegnitvene spodbude za inovativna zdravila.
The existing landscape has to be taken into account in the discussion about novel incentives or other mechanisms to address market failures with regard to the development of antimicrobials. 
V razpravi o novih spodbudah ali drugih mehanizmih za odpravo nedelovanja trga v zvezi z razvojem antimikrobikov je treba upoštevati obstoječe razmere.
72 The Commission has set out its overarching research strategy in its European One Health Action Plan against AMR, and it has funded the JPIAMR Strategic Research and Innovation Agenda. 
Komisija je svojo splošno raziskovalno strategijo določila v Evropskem akcijskem načrtu „eno zdravje“ zoper odpornost proti antimikrobikom ter vzpostavila strateški program za raziskave in inovacije, tj. skupno načrtovalno pobudo za zajezitev antimikrobične odpornosti.
73 Some antibiotics that continue to work are withdrawn from the market. 
Nekateri antibiotiki, ki še naprej delujejo, so umaknjeni s trga.
This is a unilateral decision of the pharmaceutical companies where the Commission has limited possibilities to influence them despite efforts to be more proactive. 
To je enostranska odločitev farmacevtskih družb, pri čemer lahko Komisija le omejeno vpliva nanje kljub prizadevanjem za bolj proaktivno delovanje.
75 The Commission, is in a process of exploring what kind of initiatives (Ňpull-mechanismsÓ) are needed in order to boost development of new antimicrobials. 
75. Komisija proučuje, katere vrste pobud („pritegnitvenih mehanizmov“) so potrebne za spodbujanje razvoja novih antimikrobikov.
At this stage, the Commission did not put forward any specific proposal, but continues the dialogue with Member States. 
Na tej točki Komisija ni predložila nobenega posebnega predloga, temveč nadaljuje dialog z državami članicami.
2 EN EN COM(2019) 128 of 11/03/2019 http://ec.europa.eu/environment/water/water-dangersub/pdf/strategic_approach_pharmaceuticals_env.PDF 3 
2 COM(2019) 128 z dne 11. marca 2019, http://ec.europa.eu/environment/water/water-dangersub/pdf/strategic_approach_pharmaceuticals_env.PDF. 3
Audit team The ECAŐs special reports set out the results of its audits of EU policies and programmes, or of management-related topics from specific budgetary areas. 
Revizijska ekipa V posebnih poročilih Evropskega računskega sodišča so predstavljeni izidi njegovih revizij politik in programov EU ali tem v zvezi z upravljanjem na posameznih področjih proračuna.
The audit was led by ECA Member Janusz Wojciechowski, then taken over by ECA Member Nikolaos Milionis at the final stage of the report, supported by Kinga Wisniewska-Danek and Kristian Sniter, Heads of Private Office, Katarzyna Radecka-Moroz, Private Office Attach; Colm Friel, Principal Manager; Stefan Den Engelsen, then Malgorzata Frydel, Head of Task; Anna Zalega, Xavier Demarche and Antonio Caruda Ruiz, Auditors; Frdrique Hussenet, Secretarial Assistant. 
Revizijo je vodil član Evropskega računskega sodišča Janusz Wojciechowski, v končni fazi poročila je vodenje prevzel član Evropskega računskega sodišča Nikolaos Milionis, pri njej pa so sodelovali vodji kabinetov Kinga Wiśniewska-Danek in Kristian Sniter, atašejka v kabinetu Janusza Wojciechowskega Katarzyna Radecka-Moroz, vodilni upravni uslužbenec Colm Friel, vodja naloge Stefan Den Engelsen, kasneje pa vodja naloge Malgorzata Frydel, revizorji Anna Zalega, Xavier Demarche in Antonio Caruda Ruiz ter tajnica Frédérique Hussenet.
From left to right: Anna Zalega, Katarzyna Radecka-Moroz, Nikolaos Milionis, Colm Friel, Malgorzata Frydel, Kristian Sniter, Xavier Demarche. 
Od leve proti desni: Anna Zalega, Katarzyna Radecka-Moroz, Nikolaos Milionis, Colm Friel, Malgorzata Frydel, Kristian Sniter, Xavier Demarche.
Š European Union, 2019. 
2019
For any use or reproduction of the following pictures that are not under the European Union copyright, please request permission directly from the copyright holders: Picture paragraph 20: Š Shutterstock / Olga Reukova Picture paragraph 37: Š Shutterstock / Dusan Petkovic Picture paragraph 46: Š Shutterstock / Billion Photos Annex II: Š UMC Utrecht - COMBACTE project PDF ISBN 978-92-847-3771-0 1977-5679 doi:10.2865/150088 QJ-AB-19-019-EN-N HTML ISBN 978-92-847-3739-0 1977-5679 doi:10.2865/487837 QJ-AB-19-019-EN-Q 
Fotografija v odstavku 46: © Shutterstock/Billion Photos. Priloga II: © UMC Utrecht – projekt COMBACTE. PDF ISBN 978-92-847-3788-8 1977-5784 doi:10.2865/66249 QJ-AB-19-019-SL-N HTML ISBN 978-92-847-3743-7 1977-5784 doi:10.2865/009780 QJ-AB-19-019-SL-Q
Antimicrobial resistance (AMR) is a growing threat to global health. 
Protimikrobna odpornost je vedno večja nevarnost za svetovno zdravje.
The EU follows a ŇOne HealthÓ approach to the problem, considering veterinary, human health, and environmental issues. 
EU uporablja zanjo pristop „eno zdravje”, v katerem upošteva veterinarsko medicino, človeško zdravje in okoljska vprašanja.
We examined how the Commission and relevant EU agencies managed their support to Member States and the EU funded research aimed at fighting antimicrobial resistance. 
Sodišče je preučilo, kako Komisija in zadevne agencije EU upravljajo svojo podporo za države članice in raziskave, namenjene boju zoper protimikrobno odpornost, ki jih financira EU.
We concluded that the activities of the Commission and agencies led to some progress. 
Ugotovilo je, da so dejavnosti Komisije in agencij prinesle nekaj napredka.
However, there is little evidence that the health burden of AMR has reduced. 
Vendar je malo dokazov, da je bilo zdravstveno breme, ki ga povzroča protimikrobna odpornost, zmanjšano.
We make recommendations to improve the CommissionŐs response to AMR through better support to Member State national action plans; promoting better monitoring and the prudent use of antimicrobials; and strengthening strategies for boosting research. 
Sodišče daje priporočila za izboljšanje odziva Komisije na protimikrobno odpornost z boljšo podporo nacionalnih akcijskih načrtov držav članic, spodbujanjem boljšega spremljanja in preudarno rabo antimikrobikov ter okrepitvijo strategij za spodbujanje raziskav.
EN 2019 Special Report 22 EU requirements for national budgetary frameworks: need to further strengthen them and to better monitor their application NO 
SL 2019 Posebno poročilo št. Zahteve EU za nacionalne proračunske okvire je treba dodatno okrepiti, njihovo uporabo pa bolje spremljati 22
Annexes Annex I – Timeline of relevant legal basis and publications Annex II – Commission’s view on the medium-term budgetary framework Annex III – Heterogeneity of independent fiscal institutions Annex IV – The fiscal rules in the preventive arm of the Stability and Growth Pact and in the Fiscal Compact Acronyms and abbreviations Glossary Replies of the Commission Audit team Timeline 3 
Priloga II – Mnenje Komisije o srednjeročnem proračunskem okviru Priloga III – Heterogenost neodvisnih fiskalnih institucij Priloga IV – Fiskalna pravila preventivnega dela Pakta za stabilnost in rast ter fiskalnega dogovora Kratice in okrajšave Glosar Odgovori Komisije Revizijska ekipa Časovnica 3
Executive summary I Seeking to remedy the root causes of the financial crisis, the Commission saw the need to complement the rules-based fiscal framework with binding national provisions. 
Povzetek I Komisija je pri prizadevanjih za odpravo temeljnih vzrokov finančne krize ugotovila, da je treba fiskalni okvir, ki temelji na pravilih, dopolniti z zavezujočimi določbami na nacionalni ravni.
It therefore proposed three legislative acts to strengthen national budgetary frameworks (i.e. the way budgetary policies are conducted). 
Predlagala je tri zakonodajne akte za okrepitev nacionalnih proračunskih okvirov (tj. način, kako se izvajajo proračunske politike).
Two of these three acts have been adopted (in 2011, as part of the ‘Six-Pack’, and in 2013, as part of the ‘Two-Pack’), while the legislative process for a proposal for a directive from 2017 is still ongoing. 
Dva od njih sta bila sprejeta (v okviru zakonodajnega šestorčka leta 2011 in v okviru zakonodajnega dvojčka leta 2013), zakonodajni postopek za predlog direktive iz leta 2017 pa še poteka.
Moreover, an intergovernmental Treaty on Stability, Coordination and Governance in the Economic and Monetary Union was signed in 2012 by 25 Member States. 
Poleg tega je 25 držav članic leta 2012 podpisalo medvladno Pogodbo o stabilnosti, usklajevanju in upravljanju v ekonomski in monetarni uniji.
II The legislative acts required Member States, among other things, to set up independent fiscal institutions, have in place national fiscal rules and introduce multiannual rule-based budgetary frameworks. 
II V zakonodajnih aktih je določeno, da morajo države članice med drugim vzpostaviti neodvisne fiskalne institucije, imeti nacionalna fiskalna pravila in uvesti večletne proračunske okvire, ki temeljijo na pravilih.
Well-designed independent fiscal institutions are associated with better compliance with fiscal rules and with accurate and less biased macroeconomic and budgetary forecasts, while medium-term budgetary frameworks are more generally recognised as contributing to stronger fiscal performance, as they show whether and how current policy decisions and future programmes fit within sustainable medium-term budget allocations. 
Dobro zasnovane neodvisne fiskalne institucije se povezujejo z večjo skladnostjo s fiskalnimi pravili ter točnimi in manj pristranskimi makroekonomskimi in proračunskimi napovedmi, za srednjeročne proračunske okvire pa običajno velja, da prispevajo k večji fiskalni uspešnosti, saj kažejo, ali in kako trenutne odločitve o politiki in prihodnji programi ustrezajo vzdržnim srednjeročnim proračunskim dodelitvam.
III The audit was aimed at assessing whether the Commission’s actions to strengthen the EU Member States’ budgetary frameworks had achieved the intended results. 
III Cilj revizije je bil oceniti, ali so ukrepi Komisije za okrepitev proračunskih okvirov držav članic EU dosegli pričakovane rezultate.